AbbVie price target raised to $195 from $187 at BMO Capital

BMO Capital raised the firm’s price target on AbbVie to $195 from $187 and keeps an Outperform rating on the shares. The analyst is citing the management’s commentary that the tail of Humira may not be felt until 2026, which is adding to confidence that Humira revenues “will be more durable”. AbbVie shares may open up to more generalists who could start to view the name as a growth option, the firm added.